The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
260
Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
Mean change from baseline to Week 8 on the Site-Rated Hamilton Anxiety Rating Scale (total score)
Time frame: Week 8
Mean change from baseline to Week 8 on the Sheehan Disability Scale (SDS) Total Score
Time frame: Week 8
Mean change from baseline to Week 8 on the Gastrointestinal Symptom Index Total Score
Time frame: Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pivotal Research Centers
Mesa, Arizona, United States
Pacific Clinical Research Medical Group
Burbank, California, United States
Us Clinical Research Centers, Llc
Costa Mesa, California, United States
Pacific Institute For Medical Research, Inc.
Los Angeles, California, United States
Affiliated Research Institute
San Diego, California, United States
Pacific Clinical Research Medical Group
Upland, California, United States
Radiant Research, Inc.
Denver, Colorado, United States
University Of Connecticut Health Center
Farmington, Connecticut, United States
Comprehensive Psychiatric Care, Pc
Norwich, Connecticut, United States
Meridien Research
Brooksville, Florida, United States
...and 41 more locations